VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma

scientific article published on 01 April 2000

VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3892/IJO.16.4.777
P698PubMed publication ID10717248

P50authorPaul LoriganQ32649737
P2093author name stringB W Hancock
R E Coleman
M H Robinson
L M El Helw
P433issue4
P921main subjectdexamethasoneQ422252
chemotherapyQ974135
P304page(s)777-782
P577publication date2000-04-01
P1433published inInternational Journal of OncologyQ6051527
P1476titleVEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma
P478volume16

Reverse relations

cites work (P2860)
Q41385777A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
Q58862182Effect of dexamethasone on voltage-gated K + channels in Jurkat T-lymphocytes
Q37340395Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
Q35941074Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.

Search more.